Effect at 3 months of early empagliflozin initiation in cardiogenic shock patients on mortality, rehospitalization, left ventricular ejection fraction and renal function. A randomized multicentric open trial. (EMPASHOCK)

Cardiogenic Shock

Hierarchical composite endpoint, assessed at 12 weeks from randomization (win-ratio method): - Rank 1: time to all-cause death or heart transplant or mechanical ventricular assist. - Rank 2: time to rehospitalization for heart failure - Rank 3: left ventricular ejection fraction assessed by echocardiography

Death at 12 weeks, Heart transplantation or long-term ventricular assistance at 12 weeks, Rehospitalization for heart failure from hospital discharge to 12-week, Left ventricular ejection fraction at 12 weeks, Left ventricular relaxation and filling pressures assessed at 12 weeks: e' wave, E/e' ratio,, Right ventricular function assessed at 12 weeks: TAPSE, S wave, Number of patients requiring extra-renal purification between randomization and 12 weeks, and evolution of renal function assessed at randomization and at 12 weeks: glomerular filtration rate calculated by the CKD-EPI method, Liver function assessed at randomization and at 12 weeks: Bilirubin, Prothrombin Ratio , SGOT, SGPT., Weight and NT-proBNP (at randomization and at 12 weeks).

No related papers found yet.

France